IDH1 and central nervous system cancer: With an in vivo sensitivity of approximately 1 mM and an ex vivo sensitivity for intact biopsies of 0.1–0.01 mM [256], MRS offers localized 2-HG quantification directly in the lesion and is well poised to differentiate between IDH wildtype and IDH mutant gliomas.